Great Chemistry Cures
At Enanta, we are committed to creating important, novel medicines by pursuing bold ideas, employing rigorous research, and striving for scientific excellence in everything we do. We are fortunate to have some of the best and brightest minds across pharma and biotech working at Enanta. We are passionate about science and dedicated to discovering and developing highly differentiated therapeutics through innovative chemistry to treat diseases in areas of high unmet need. These efforts have resulted in developing drugs for combination regimens that have cured more than one million people with chronic hepatitis C virus infection. It’s incredibly rewarding for our scientific expertise to have such an impact on patients’ lives, and this drives us to do it again in other disease areas.
Great Chemistry Cures
At Enanta, we are committed to creating important, novel medicines by pursuing bold ideas, employing rigorous research, and striving for scientific excellence in everything we do. We are fortunate to have some of the best and brightest minds across pharma and biotech working at Enanta. We are passionate about science and dedicated to discovering and developing highly differentiated therapeutics through innovative chemistry to treat diseases in areas of high unmet need. These efforts have resulted in developing drugs for combination regimens that have cured more than one million people with chronic hepatitis C virus infection. It’s incredibly rewarding for our scientific expertise to have such an impact on patients’ lives, and this drives us to do it again in other disease areas.
About Us
Enanta’s heritage is steeped in scientific expertise and a track record of effective innovation. Without either, we wouldn’t be where we are today. We are dedicated to applying these capabilities and experience each day in hopes of improving patients’ lives. We’ve done it before, and we’re determined to do it again.
June 11, 2025
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
May 27, 2025
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 22, 2025
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting